Skip to Main content Skip to Navigation
Journal articles

Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis

Eric Trépo 1, 2, * Nicolas Goossens 3, 4 Naoto Fujiwara 3 Won-Min Song 3, 5 Antonio Colaprico 6, 7 Astrid Marot 8 Laurent Spahr 4 Pieter Demetter 9 Christine Sempoux 10 Gene Im 11 Joan Saldarriaga 10 Thierry Gustot 1, 2 Jacques Devière 1, 2 Swan Thung 3 Charlotte Minsart 2 Thomas Sersté 1 Gianluca Bontempi 6, 7 Karim Abdelrahman 8 Jean Henrion 12 Delphine Degré 1, 2 Valerio Lucidi 13 Laura Rubbia-Brandt 14 Venugopalan Nair 15 Christophe Moreno 1, 2 Pierre Deltenre 1, 8, 16 Yujin Hoshida 3, * Denis Franchimont 1, 2
* Corresponding author
1 Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology [Brussels, Belgium]
2 Laboratory of Experimental Gastroenterology [Brussels, Belgium]
3 Department of Medicine [New York]
4 Division of Gastroenterology and Hepatology [Geneva, Switzerland]
5 Department of Genetics and Genomic Sciences
6 IB2 - Interuniversity Institute of Bioinformatics in Brussels
7 Department d'Informatique - Machine Learning Group [Brussels, Belgium]
8 Division of Gastroenterology and Hepatology [Lausanne, Switzerland]
9 Department of Pathology [Brussels, Belgium]
10 Department of Clinical Pathology [Lausanne, Switzerland]
11 Recanati/Miller Transplantation Institute [New York, NY, USA]
12 Unité d'Hématologie [CH de Jolimont-Lobbes, Belgium]
13 Department of Abdominal Surgery [Brussels, Belgium]
14 Clinical Pathology Division - Department of Pathology and Immunology [Geneva, Switzerland]
15 Department of Neurology [New York, NY, USA]
16 Service d'Hépato-Gastroentérologie [Haine-Saint-Paul, Belgium]
Abstract : BACKGROUND & AIMS: Patients with severe alcoholic hepatitis (AH) have a high risk of death within 90 days. Corticosteroids, which can cause severe adverse events, are the only treatment that increases short-term survival. It is a challenge to predict outcomes of patients with severe AH. Therefore, we developed a scoring system to predict patient survival, integrating baseline molecular and clinical variables. METHODS: We obtained fixed liver biopsy samples from 71 consecutive patients diagnosed with severe AH and treated with corticosteroids from July 2006 through December 2013 in Brussels, Belgium (derivation cohort). Gene expression patterns were analyzed by microarrays and clinical data were collected for 180 days. We identified gene expression signatures and clinical data that are associated with survival without liver transplantation at 90 and 180 days after initiation of corticosteroid therapy. Findings were validated using liver biopsies from 48 consecutive patients with severe AH treated with corticosteroids, collected from March 2010 through February 2015 at hospitals in Belgium and Switzerland (validation cohort 1) and in liver biopsies from 20 patients (9 received corticosteroid treatment), collected from January 2012 through May 2015 in the United States (validation cohort 2). RESULTS: We integrated data on expression patterns of 123 genes and the model for end-stage liver disease (MELD) scores to assign patients to groups with poor survival (29% survived 90 days and 26% survived 180 days) and good survival (76% survived 90 days and 65% survived 180 days) (P < .001) in the derivation cohort. We named this assignment system the gene signature-MELD (gs-MELD) score. In validation cohort 1, the gs-MELD score discriminated patients with poor survival (43% survived 90 days) from those with good survival (96% survived 90 days) (P < .001). The gs-MELD score also discriminated between patients with a poor survival at 180 days (34% survived) and a good survival at 180 days (84% survived) (P < .001). The time-dependent area under the receiver operator characteristic curve for the score was 0.86 (95% confidence interval 0.73-0.99) for survival at 90 days, and 0.83 (95% confidence interval 0.71-0.96) for survival at 180 days. This score outperformed other clinical models to predict survival of patients with severe AH in validation cohort 1. In validation cohort 2, the gs-MELD discriminated patients with a poor survival at 90 days (12% survived) from those with a good survival at 90 days (100%) (P < .001). CONCLUSIONS: We integrated data on baseline liver gene expression pattern and the MELD score to create the gs-MELD scoring system, which identifies patients with severe AH, treated or not with corticosteroids, most and least likely to survive for 90 and 180 days.
Keywords : Cirrhosis Ethanol MELD Transcription
Document type :
Journal articles
Complete list of metadatas

Cited literature [43 references]  Display  Hide  Download
https://www.hal.inserm.fr/inserm-02312733
Contributor : Anne Daulny <>
Submitted on : Friday, October 11, 2019 - 11:40:54 AM
Last modification on : Wednesday, June 10, 2020 - 10:22:05 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

INSERM

Citation

Eric Trépo, Nicolas Goossens, Naoto Fujiwara, Won-Min Song, Antonio Colaprico, et al.. Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis. Gastroenterology, WB Saunders, 2018, 154 (4), pp.965-975. ⟨10.1053/j.gastro.2017.10.048⟩. ⟨inserm-02312733⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

106